文献速递膀胱癌与上尿路尿路上皮癌

根治性肾输尿管切除术质量指标的 externally validation

External validation of current quality care metrics after radical nephroureterectomy.
PubMed 文献 · BJU Int · 2025-04-20

本研究在545例局限性上尿路尿路上皮癌患者中外部验证tetrafecta和pentafecta质量框架,发现29.5%和34.5%的患者分别达成二者,且与更好的肿瘤学结局相关,pentafecta对OS预后价值更强。

要点

  • tetrafecta和pentafecta与更好的OS、RFS相关。
  • pentafecta是OS和CSS的独立预测因素。
  • 两框架对OS和CSS预测准确性高(AUC>0.9)。

核心结论

  • tetrafecta和pentafecta是评估局限性UTUC行RNU后肿瘤学结局的可靠工具。

研究设计与样本

  • 回顾性研究,纳入2012至2023年间在8家法国大学医院和1家黎巴嫩大学医院接受RNU的545例局限性UTUC患者。

主要发现

  • 29.5%患者达成tetrafecta,34.5%达成pentafecta。
  • 达成tetrafecta者3年OS为90.1% vs 74.2%(P<0.001),3年RFS为84.5% vs 57.6%(P<0.001)。
  • 达成pentafecta者3年OS为89.4% vs 73.4%(P<0.001),3年RFS为83.5% vs 56%(P<0.001)。
  • tetrafecta和pentafecta对OS的AUC分别为0.92和0.93(P=0.41),对CSS的AUC分别为0.944和0.945(P=0.6018)。
  • 多因素分析中,pentafecta与更好的OS独立相关(HR 0.30,95%CI 0.16-0.55,P<0.001),与更好的CSS独立相关(HR 0.24,95%CI 0.10-0.54,P<0.001)。

关键数值与推荐

  • tetrafecta需满足:手术切缘阴性、完整膀胱袖状切除、必要时行淋巴结清扫、12个月内无复发。
  • pentafecta在tetrafecta基础上增加无major并发症或血液学事件。

临床怎么用

  • 这些指标可标准化评估手术质量、指导临床决策并向患者咨询预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To externally validate the tetrafecta and pentafecta frameworks for assessing the quality of radical nephroureterectomy (RNU) and their correlation with oncological outcomes in patients with localised upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: This retrospective study included 545 patients who underwent RNU for localised UTUC between 2012 and 2023 at eight French university hospitals and one Lebanese university hospital. Achievement of tetrafecta required four criteria to be met: negative surgical margins, complete bladder cuff excision, lymph node dissection (if indicated), and absence of recurrence within 12 months. Pentafecta consisted of the same criteria, plus no major complications or haematological events. Oncological outcomes assessed included intravesical recurrence-free survival (IVRFS), recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS). Kaplan-Meier analyses, Cox regression, and calibration plots were used to evaluate the predictive performance of the frameworks for 3-year outcomes. RESULTS: A total of 29.5% of our cohort achieved tetrafecta and 34.5% achieved pentafecta. Patients meeting either of these quality care metrics demonstrated significantly improved oncological outcomes, with higher 3-year OS rates (tetrafecta: 90.1% vs 74.2%, P < 0.001; pentafecta: 89.4% vs 73.4%, P < 0.001) and RFS rates (tetrafecta: 84.5% vs 57.6%, P < 0.001; pentafecta: 83.5% vs 56%, P < 0.001). Both metrics showed high predictive accuracy for OS (area under the curve [AUC] 0.92 for tetrafecta; 0.93 for pentafecta, P = 0.41) and CSS (AUC 0.944 for tetrafecta; 0.945 for pentafecta, P = 0.6018). Pentafecta achievement was independently associated with better OS and CSS in multivariable analysis (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.16-0.55, P < 0.001 and (HR 0.24, 95% CI 0.10-0.54, P < 0.001, respectively). CONCLUSION: Tetrafecta and pentafecta are reliable tools for assessing oncological outcomes after RNU in localised UTUC. Pentafecta demonstrated stronger prognostic value for OS, particularly in high-risk populations. These metrics offer a standardised framework to guide clinical decisions, evaluate surgical quality, and counsel patients about prognosis.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Duquesne I, Gabriel PE, Chakra MA, et al. External validation of current quality care metrics after radical nephroureterectomy. BJU Int. 2025. PMID: 40254784. doi:10.1111/bju.16741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。